tions, including my own father, with silver hydrosol. There’s absolutely no chance of developing argyria, which is excessive ac- cumulation of silver, and the silver in Ar- gentyn 23 and Sovereign Silver is so fine that it does not trigger any type of foreign body reaction in the lungs. It bears repeating that I cannot attest

to the efficacy of silver hydrosol against SARS-CoV-2. It’s a new virus, and so the studies just aren’t there. What I can say is that Bio-Active Silver Hydrosol™ has been used to successfully eradicate other corona viruses, specifically SARS and MERS. My recommendation is to for people

to first proactively use Bio-Active Silver Hydrosol™ 1 teaspoon 3 times daily as a powerful preventative to build up their immune system. NOTE: Do not mix silver hydrosol with ANYTHING other than distilled water. It will inactivate it.

The Case for Chloroquine What’s all the confusion about these

drugs? Thursday evening, March 19, 2020, I attended a web conference by Dr. Diet- rich Klinghardt MD PhD, who is widely known for his expertise in unusual infec- tions and illnesses. He explained that neither chloroquine nor hydroxychloro- quine kill the virus. They act as ionophores for zinc. That means that the drugs enhance the ability of zinc to enter the cells of your body and zinc then blocks the cellular machinery that makes baby viruses. I endorse further studies, but for good- ness sake, don’t deny the drug to people who are sick! The French and Chinese have already shown that it works, as have the

Koreans. It will work better with enough zinc. I suggest checking zinc levels in the studies and/or putting everyone on zinc as recommended earlier, since most people are zinc deficient. Remember, the drugs work optimally with enough zinc present. Dr. Klinghardt also shared recent ar- ticles that are primarily coming out of China and France that discuss the use of chloroquine—and alternatively hydroxy- chloroquine and azithromycin—for treat- ment of acute pneumonia with SARS- CoV-2.

• A study released on February 4 from China by Wang, M. et al (xxv) showed that chloroquine phosphate (CQ) effec- tively inhibited the growth of SARS- CoV-2 in vitro i.e. not in patients, but in the laboratory in a test tube.

• A February 20 consensus paper from China by Zhonghua, et al (xxvi) recom- mended that patients with SARS-CoV-2 pneumonia receive CQ 500 mg twice daily in a tablet form for 10 days since this drug has shown good activity against other coronaviruses. Initial results were promising, and others are ongoing.

• Another study out of France by Gautret, P. et al (xxvii) published on March 17 showed that hydroxychloroquine (a cousin of CQ) combined with azithromy- cin (Zithromax Z-Pak) reduced the amount of the virus that they were carry- ing by day six. This combo shortened the duration of infection. The authors suggest that:

Daniel Lackey, FNP-C is a board certified Nurse Practitioner. His background is in Emergency Medi- cine, with 5 years of experience as an ER nurse. His nurse practitioner degree includes specialties in fami- ly practice and adult gerontological acute care. Following his true pas- sion, however, he also obtained a certification in functional medi- cine. He finds it is truly rewarding and efficacious to address the root cause of illness instead of viewing the body as separate systems.

Among candidate drugs to treat SARS- CoV-2, repositioning [or repurposing] of old drugs for use as antiviral treatment is an interesting strategy because knowl- edge on dosing, safety profile, side ef- fects, and drug interactions are well known.

…Hydroxychloroquine (an analogue of chloroquine) has been demonstrated to have an anti-SARS-CoV-2 activity in vitro. Hydroxychloroquine clinical safety pro- file is better than that of chloroquine (during long-term use) and allows higher daily dose and has fewer concerns about drug-drug interactions.

…Azithromycin added to hydroxychlo- roquine was significantly more efficient for virus elimination.

Perhaps this is due to its inherent anti-inflammatory effect, which is sepa- rate from its antibiotic effect? This was an open label, non-randomized clinical trial. There were a total of 40 patients. The 20 in the treatment group were cured!

• On March 23 an article by Dr. Jeff Colyer and Dr. Daniel Hinthorn entitled, These Drugs Are Helping Our COVID–19 Patients (xxviii) was published on the opinion page of the Wall Street Journal. They used the protocol outlined from China for treatment of patients with SARS-CoV-2, employing the use of chlo- roquine with success; however, they then switched to the combination described in the above French study using Zithro- max and hydroxychloroquine. They stated,

Our experience suggested hydroxychlo- roquine, with or without a Z-Pak, should be a first line treatment. Unfortunately, there’s already a shortage of hydroxychlo- roquine. The federal government should immediately contract with generic manu- facturers to ramp up production. Any stockpiles should be released... Rapid and strategic use of these drugs could help arrest the spread of the disease. They also stated that,

…the public expects an answer, and we don’t have the luxury of time. We have a drug with an excellent safety profile but limited clinical outcomes—and no better alternatives until long after this disaster